Cocoon Bioscience
Scientist
on
September 23, 2025
This installment of Supplier Spotlight® highlights Cocoon Bioscience, a recombinant enzyme manufacturer for life sciences applications who leverage nature to enable innovation. Their services are available on Scientist.com.
1. What is your company’s mission?
Cocoon Bioscience’s mission is to accelerate the development and accessibility of advanced therapies by providing high-quality, affordable recombinant enzymes and custom solutions for our partners. We are committed to forging strategic partnerships that reinforce the life sciences ecosystem and foster innovation, supporting researchers and organizations throughout every stage of development.
2. What products and services do you offer?
We provide a portfolio of off-the-shelf enzymes for in vitro transcription (IVT), ensuring researchers have immediate access to reliable and high-performance tools. Beyond standard products, we also offer a custom enzyme development service, tailored for projects based on our clients’ needs that require improved performance or novel functionalities, or more efficient production outputs — often enabling a more competitive cost structure. In parallel, we focus on OEM/white label specialized enzymes for kit manufacturers, supporting their need for consistent quality, scalability and differentiation in an increasingly competitive diagnostics and life sciences market.
3. What problems do you solve?
Cocoon Bioscience helps the life sciences industry by providing high-quality, cost-effective enzymes for in vitro transcription. Our solutions combine affordable pricing with reliable supply and consistent performance, ensuring research and development projects stay on track. We also offer custom enzyme development to enhance efficiency, yield and functionality for specialized applications.
4. What are the most innovative tools and technologies that you offer?
Our unique recombinant expression platform utilizes nature-based bioreactors, integrated with automation and AI technologies, to efficiently produce high-quality enzymes at scale while allowing flexible volume adaptations for diverse applications. This approach delivers cost-effective enzyme solutions without the need for CAPEX-intensive bioreactors, while ensuring continuity, reliability and reproducibility across research projects.
5. What are your competitive advantages?
We provide cost-effective enzyme solutions — both off-the-shelf and custom-developed — combined with scalability, speed, adaptability and global proximity through our distribution in the US and Europe. This enables researchers and manufacturers to accelerate development, optimize performance for their specific applications and maintain smooth, uninterrupted project workflows.
6. Who are your clients?
Our clients are mainly biotechnology and pharmaceutical companies advancing mRNA and gene therapy programs. We collaborate with early-stage biotech companies pioneering RNA-based therapeutics as well as established pharma firms strengthening their research pipelines.
7. What new products and services are you developing in 2025/2026?
Our main priority for the end of this year and 2026 is the expansion of our specialty enzyme portfolio. This includes products such as T4 DNA Ligase, Thermostable Inorganic Pyrophosphatase and a broader range of enzymes essential to mRNA and plasmid DNA workflows. With these offerings, we aim to support next-generation applications in life sciences, from cutting-edge molecular biology research to the development and manufacturing of advanced therapeutics. In parallel, we are also exploring complementary services that streamline access to these enzymes, ensuring our partners benefit from both innovative products and reliable, scalable production tailored to their needs.
8. Where are your laboratories and offices located?
Our headquarter is located in the Technology Park of Derio, in Spain’s biotech hub, the Basque Country, where we operate a 2,300 m² industrial facility adhere to GMP standards and is ISO 9001 certified. The site encompasses laboratories, insect-rearing units and downstream purification operations, supporting an annual production capacity of more than 20 kilograms of recombinant protein. In addition, we have an R&D laboratory in Tres Cantos, on the outskirts of Madrid.